Display options
Cite
Agrawal I, Tripathi P, Biswas S. Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases. Drug Metab Rev. 2022;1-17doi: 10.1080/03602532.2022.2029475.
Agrawal, I., Tripathi, P., & Biswas, S. (2022). Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases. Drug metabolism reviews, 1-17. https://doi.org/10.1080/03602532.2022.2029475
Agrawal, Ishita, et al. "Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases." Drug metabolism reviews vol. (2022): 1-17. doi: https://doi.org/10.1080/03602532.2022.2029475
Agrawal I, Tripathi P, Biswas S. Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases. Drug Metab Rev. 2022 Jan 17;1-17. doi: 10.1080/03602532.2022.2029475. Epub 2022 Jan 17. PMID: 35038284.
Copy Download .nbib Format: NLM
Share it on

Drug Metab Rev. 2022 Jan 17;1-17. doi: 10.1080/03602532.2022.2029475. Epub 2022 Jan 17.

Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases.

Drug metabolism reviews

Ishita Agrawal, Pallavi Tripathi, Shyamasri Biswas

Affiliations

  1. Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India.
  2. Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, M1 7DN, Manchester, UK.
  3. USA Prime Biotech LLC, 1330 NW 6th St., Suite A-2, Gainesville, FL 32601, USA.

PMID: 35038284 DOI: 10.1080/03602532.2022.2029475

Abstract

Neurodegenerative diseases correspond to overly complex health disorders that are driven by intersecting pathophysiology that are often trapped in vicious cycles of degeneration and cognitive decline. The usual diagnostic route of these diseases is based on postmortem examination that involves identifying pathology that is specific to the disease in the brain. However, in such cases, accurate diagnosis of the specific disease is limited because clinical disease presentations are often complex that do not easily allow to discriminate patient's cognitive, behavioral, and functional impairment profiles. Additionally, an early identification and therapeutic intervention of these diseases is pivotal to slow the progression of neurodegeneration and extend healthy life span. Mass spectrometry-based techniques have proven to be hugely promising in biological sample analysis and discovery of biomarkers including protein and peptide biomarkers for potential drug target discovery. Recent studies on these biomarkers have demonstrated their potential for applications in early diagnostics and identifying therapeutic targets to battle against neurodegenerative diseases. In this review, we have presented principles of mass spectrometry (MS) and the associated workflows in analyzing and imaging biological samples for discovery of biomarkers. We have especially focused on age- related progressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD) and the related MS-based biomarkers developments for these diseases. Finally, we present a future perspective discussing the potential research directions ahead.

Keywords: LC-MS/MS; MALDI-TOF; biomarkers; cerebrospinal fluid; drug targets; neurodegeneration; plasma; proteomics

Publication Types